TRT and Your Prostate: PSA, Cancer Risk, and BPH Explained

For decades, doctors treated testosterone like gasoline near a fire when it came to the prostate. The thinking went like this: prostate cancer feeds on testosterone, so giving a man more testosterone must feed the cancer. That idea shaped how testosterone replacement therapy (TRT) was prescribed, warned about, and feared. The problem is that the science underneath it was thin, and the modern evidence points somewhere else entirely.

This guide walks through what we actually know in 2026 about TRT and prostate health: what testosterone does to your PSA, whether it raises your risk of prostate cancer, how it affects benign prostate enlargement and urinary symptoms, and what a careful monitoring plan looks like. The goal is balance. Not hype, not fear. If you have low testosterone with real symptoms, the decision is yours to make with a prescriber who will watch your numbers over time.

Medical disclaimer: This article is for education only and is not medical advice. It does not replace a conversation with a licensed clinician who knows your history. Prostate cancer screening and TRT decisions should be made with a doctor. Do not start, stop, or change testosterone based on what you read here.

Quick Answer: Is TRT Safe for Your Prostate?

• TRT does not appear to cause prostate cancer. The largest randomized trial to date (TRAVERSE, 5,204 men) found prostate cancer rates were not higher with testosterone than with placebo, and big pooled studies show no link between natural testosterone levels and prostate cancer risk.
• Testosterone can nudge your PSA up a little, usually a small bump in the first 6 to 12 months. A large or fast PSA rise is the signal that triggers a closer look, not the testosterone itself.
• TRT does not reliably worsen urinary symptoms from an enlarged prostate (BPH). Some men's urinary symptoms actually improve; the average effect on prostate size is small.
• Monitoring is non-negotiable. Major guidelines call for a PSA check and prostate exam before starting and again within the first year, with referral if PSA jumps past set thresholds.

Does TRT Cause Prostate Cancer?

The short answer, based on the best evidence we have: no, not as far as the data can show. This is one of the biggest reversals in men's health over the past 20 years, so it's worth understanding where the old fear came from and why it has faded.

The fear traces back to 1941, when researchers Charles Huggins and Clarence Hodges showed that lowering testosterone (through castration) shrank advanced prostate cancer, and that giving testosterone could make it grow. That work won a Nobel Prize and saved lives. But it was done in a tiny number of men who already had advanced, metastatic disease. The leap that followed, that testosterone causes prostate cancer in healthy men, was never actually proven. It just became conventional wisdom.

Modern data tells a different story. A landmark collaborative analysis pooled 18 prospective studies and found no association between a man's blood testosterone level and his risk of developing prostate cancer (Endogenous Hormones and Prostate Cancer Collaborative Group, Journal of the National Cancer Institute, 2008). Men with naturally high testosterone were not at higher risk than men with low testosterone. If testosterone fueled prostate cancer the way the old model suggested, you would expect to see that link. It isn't there.

Then came the trial that mattered most. The TRAVERSE study randomized 5,204 men with low testosterone and high cardiovascular risk to either testosterone gel or placebo and followed them for an average of about 33 months. On the prostate side, the results were reassuring: rates of any prostate cancer, high-grade prostate cancer, urinary retention, prostate surgery, and new prostate medications were low and did not differ between the testosterone and placebo groups (Bhasin et al., JAMA Network Open, 2023).

What the evidence says, at a glance

A note on that fourth row, because it surprises people. Several observational studies have found that men diagnosed with prostate cancer who have low testosterone tend to have more aggressive, higher-grade tumors, not less. Low testosterone is not a shield. That doesn't mean low T causes aggressive cancer, but it firmly kills the idea that keeping testosterone low protects the prostate.

Why Was Everyone So Scared, Then?

Because the old logic felt airtight, and because PSA, the blood marker we use to screen for prostate cancer, does react to testosterone. When a man with very low testosterone starts TRT, his PSA often rises a little. To a clinician trained in the old model, a rising PSA looked like a warning sign of cancer waking up. We now understand most of that rise differently (more on that below).

The reversal is now reflected in policy. In February 2025, the U.S. Food and Drug Administration (FDA) issued class-wide labeling changes for all testosterone products. It removed the boxed warning about cardiovascular risk, added the TRAVERSE results to the label, and required a new warning about blood pressure (FDA Drug Safety Communication, February 28, 2025). The label still tells doctors to screen and monitor the prostate, which is the right call. But the framing has shifted from "this might cause cancer" to "screen, monitor, and proceed thoughtfully."

This mirrors the cardiovascular story. For years TRT carried a heart-attack warning that the best trial evidence didn't support. If you want the full picture on that, our guide on TRT side effects and safety covers the heart, blood, and other risks in detail.

What Is the Saturation Model, and Why Does It Matter?

The saturation model is the idea that best explains why TRT can be safe for the prostate even though prostate tissue clearly responds to testosterone.

Here's the plain-English version. Prostate cells have receptors that grab onto androgens (testosterone and its stronger cousin, DHT). Think of those receptors like parking spots. When testosterone is very low, near-castrate levels, the parking lot is mostly empty, and adding testosterone fills spots fast, driving prostate activity up. But the lot is small. It fills, or "saturates," at a fairly low testosterone level, somewhere in the low-normal range. Once every spot is taken, pouring in more testosterone doesn't do much more, because there's nowhere left to park.

This is why a man going from a testosterone of 150 ng/dL up to 500 ng/dL may see a small PSA bump (he's filling empty spots), while a man going from 500 to 900 typically sees little prostate effect (the lot was already full). It's also why men with normal baseline testosterone show essentially no PSA change on therapy.

The saturation model isn't a perfect or universally accepted law of nature, and some researchers have pushed back on parts of it. But it fits the clinical data well, and it lines up neatly with what we see: a small early PSA rise in deeply low men, and very little in everyone else.

How Much Will TRT Raise My PSA?

Usually a little, usually early, and usually not enough to alarm anyone. The magnitude depends on how low your testosterone was to begin with.

In a controlled trial of older hypogonadal men, PSA rose by an average of about 0.47 ng/mL at 12 months on testosterone, compared with roughly 0.06 ng/mL on placebo. In men who were severely hypogonadal, the bump was bigger, a median rise of about 0.70 ng/mL, because they had the most "empty parking spots" to fill.

Typical PSA changes on TRT

The practical takeaway: a modest PSA rise in the first several months of TRT is often the prostate "re-calibrating" to a normal hormonal environment, not a sign of cancer. What matters is how big the rise is and how fast it happens. That's why your doctor takes a baseline PSA first. Without a baseline, a single PSA number on TRT is hard to interpret.

Because PSA reacts to so many things, the first few months of TRT are not the time to guess. Track it. Our deep dive on TRT blood work and the monitoring schedule lays out exactly which labs to run and when.

What PSA Numbers Trigger a Closer Look?

This is where guidelines get specific, and specificity is your friend. The Endocrine Society's clinical practice guideline gives clinicians clear thresholds for when to send a man on TRT to a urologist (Bhasin et al., Journal of Clinical Endocrinology & Metabolism, 2018).

During the first 12 months of testosterone treatment, urological evaluation is recommended if there's:

• A confirmed PSA rise of more than 1.4 ng/mL above baseline, or
• A confirmed PSA above 4.0 ng/mL, or
• A prostate abnormality felt on a digital rectal exam (DRE).

The word "confirmed" matters. PSA is a noisy test. It bounces with infection, recent ejaculation, a bike ride, or just lab variability. One high reading isn't a diagnosis; it's a reason to repeat the test before acting. A 2024 review of prostate risk and monitoring during TRT stresses exactly this point: a structured, threshold-based plan lets doctors catch the cancers that matter while avoiding needless biopsies over small, expected wiggles (Bhasin and Thompson, Journal of Clinical Endocrinology & Metabolism, 2024).

Prostate monitoring checklist for men on TRT

Higher-risk men include those of African descent and men with a father or brother who had prostate cancer. If that's you, the conversation about prostate screening should start earlier and run a bit more cautiously. That's not a reason to avoid TRT; it's a reason to monitor with extra care.

Does TRT Make BPH and Urinary Problems Worse?

This is the other big prostate fear, separate from cancer. Benign prostatic hyperplasia (BPH) is the non-cancerous enlargement of the prostate that's almost universal as men age. It can squeeze the urethra and cause the classic lower urinary tract symptoms (LUTS): weak stream, dribbling, getting up at night to pee, urgency, and trouble fully emptying.

The old worry was that adding testosterone would feed the enlargement and make urination worse. The evidence is more reassuring than that.

A systematic review and meta-analysis of testosterone therapy and urinary symptoms found that TRT did not worsen LUTS, and in men with low testosterone, symptoms scores (measured by the International Prostate Symptom Score, or IPSS) often stayed flat or improved (Kohn et al., European Urology, 2016). Longer-term observational data points the same way: voiding function tends to hold steady or get a little better, and changes in actual prostate volume are small.

That said, "on average" is not "for everyone." A minority of men do notice urinary changes, and if you already have significant BPH, your prescriber should factor that in. The point is that BPH is generally not a hard stop for TRT; it's a reason for a thoughtful conversation and follow-up.

TRT and BPH/urinary symptoms

What If I've Had Prostate Cancer? Can I Still Use TRT?

This is the hardest and most individual question in the whole topic, and it's genuinely different from "does TRT cause cancer." Here the cancer already exists or existed. The honest answer: it depends, and it requires a urologist or oncologist on your team.

For men who've had prostate cancer fully treated, with surgery (radical prostatectomy) or radiation, and who have low testosterone with symptoms, a growing body of evidence suggests TRT may be reasonable in carefully selected cases. Recent reviews of men treated for localized prostate cancer have not found a clear increase in recurrence among those given testosterone afterward. But these are mostly smaller, observational studies, not large randomized trials, so the evidence is "encouraging" rather than "settled."

For men with active, untreated prostate cancer or those on active surveillance, the calculus is more cautious and very individual. The American Urological Association is clear that men with a history of prostate cancer should be told there's inadequate evidence to fully quantify the risk and benefit, and that any decision needs careful counseling (AUA Testosterone Deficiency Guideline).

The bottom line: a prostate cancer history is not an automatic, permanent ban on TRT the way it once was, but it moves the decision out of the "telehealth checkbox" zone and into the hands of a specialist who knows your specific cancer.

How Do I Pick a Provider Who Monitors This Right?

The prostate is exactly where a careless TRT operation gets dangerous, not because testosterone is dangerous, but because skipping the baseline PSA and the follow-up labs means you lose the early-warning system. The therapy is safe largely because of the monitoring around it.

A good provider will, at minimum:

• Order a baseline PSA before your first dose (and discuss a DRE based on your age and risk).
• Re-check PSA within the first year and respond to the guideline thresholds above.
• Know when to refer you to a urologist instead of pushing through an abnormal result.
• Take a real history, family history of prostate cancer, ethnicity, urinary symptoms, rather than treating you as a number on a form.

If a clinic is willing to start you on testosterone without a baseline PSA, that's a red flag. Use our guide to choosing a TRT provider to vet telehealth versus in-person options, and browse vetted TRT providers or compare clinics side by side before you commit. If cost is part of your decision, the TRT cost calculator helps you estimate the real monthly number, including the lab work that keeps your prostate monitoring on track.

Putting It All Together

The fear that testosterone causes prostate cancer was built on a small 1940s study and held up for decades on logic alone. The modern evidence, including the largest randomized trial we have, the FDA's 2025 label update, and pooled data on tens of thousands of men, points to a calmer reality: TRT, in men who are screened and monitored, is not the prostate threat it was made out to be.

That word, monitored, is the whole ballgame. A baseline PSA, a repeat within the year, and a doctor who knows the referral thresholds turn TRT from a leap of faith into a managed, low-risk decision. The testosterone isn't the risk. Flying blind is.

Frequently Asked Questions

1. Will TRT give me prostate cancer? There's no good evidence that TRT causes prostate cancer. The largest randomized trial (TRAVERSE) found no increase in prostate cancer versus placebo, and pooled studies show no link between natural testosterone levels and prostate cancer risk. What TRT can do is reveal a cancer that was already there by nudging PSA up, which is exactly why monitoring matters.

2. How much will my PSA go up on testosterone? Usually a little, mostly in the first 6 to 12 months. Men with very low starting testosterone may see a rise of around 0.5 to 0.7 ng/mL; men with normal baseline testosterone often see almost no change. A confirmed rise of more than 1.4 ng/mL in the first year, or a PSA above 4.0, is the signal to pause and see a urologist.

3. Can I take TRT if I have an enlarged prostate (BPH)? Usually yes. Studies show TRT generally doesn't worsen urinary symptoms, and some men actually improve. Severe BPH calls for caution and monitoring, but it's rarely an absolute reason to avoid testosterone. Talk it through with your prescriber.

4. Do I really need a PSA test before starting TRT? Yes. A baseline PSA is essential. Without it, any PSA value measured later on TRT is hard to interpret, you can't tell a normal small bump from a meaningful jump. Both the Endocrine Society and the AUA recommend baseline prostate screening before starting, with follow-up within the first year.

5. I had prostate cancer years ago. Is TRT off the table forever? Not necessarily. For men whose cancer was fully treated, early evidence suggests carefully selected men can use TRT without a clear rise in recurrence, but this decision belongs with a urologist or oncologist, not a quick telehealth visit. The evidence is encouraging but not yet settled.

Related Guides

• TRT Side Effects & Safety: What the Evidence Says
• TRT Blood Work: The Labs & Monitoring Schedule
• How to Choose a TRT Provider: Telehealth vs In-Person
• Do I Need TRT? Low-Testosterone Symptoms & How It's Diagnosed
• How Much Does TRT Cost?

Sources

• Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute, 2008. PMID 18230794
• Bhasin S, Travison TG, Pencina KM, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Network Open, 2023. PMID 38150256
• Bhasin S, Thompson IM. Prostate Risk and Monitoring During Testosterone Replacement Therapy. Journal of Clinical Endocrinology & Metabolism, 2024. PMID 38753865
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 2018. PMID 29562364 (guideline resources)
• Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis. European Urology, 2016. PMID 26874809
• U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. February 28, 2025. FDA.gov
• American Urological Association. Evaluation and Management of Testosterone Deficiency: AUA Guideline. AUAnet.org